Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week: Onyx Proteolix, Novartis/Heptares, Wyeth/Progenics ...

Executive Summary

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

You may also be interested in...



Deals Of The Week: Shire/Heptares, NicOx/Altacor, UCB/Oxford University

This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.

Shire To Strengthen CNS Focus With Option On Heptares' Novel Parkinson's Therapy

Shire Pharmaceuticals takes an option on Heptares' efforts to develop novel adenosine antagonists for Parkinson's disease.

Shire To Strengthen CNS Focus With Option On Heptares' Novel Parkinson's Therapy

Shire Pharmaceuticals takes an option on Heptares' efforts to develop novel adenosine antagonists for Parkinson's disease.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel